Lonza began the expansion of its bioconjugation facility in Visp, Switzerland together with the successful commercial approval of a third antibody-drug-conjugate (ADC) produced at the site. Lonza’s expansion aims to meet the development and manufacturing needs of pharma and biotech companies developing a new generation of therapies.    Increasing demand from customers has prompted Lonza to commence an expansion that will span the next two years. The additional capacity, with contracts already ...